Compare Inovio Pharmaceuticals Inc (INO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while abrdn Physical Palladium Shares ETF trades at $20.78 (market cap $586.03M). The key difference: abrdn Physical Palladium Shares ETF is far larger — about 5.2× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| INO | PALL | |
|---|---|---|
Market Cap | $112.19M | $586.03M |
Volume | 3,201,278 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.65 | $37.18 |
52-Week Low | $0.66 | $20.30 |
Typical Hold Time | 43 Days | 33 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
